Publications

'For a mere cough, men must just chew Conjex, gain strength, and continue working': the provider construction and tuberculosis care-seeking implications in Blantyre, Malawi.

Chikovore, J; Hart, G; Kumwenda, M; Chipungu, GA; CORBETT, L;

2015

Global health action, (2015).8 1 10.3402/gha.v8.26292.

Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial.

Chihota, VN; Ginindza, S; McCarthy, K; GRANT, AD; CHURCHYARD, G; FIELDING, K;

2015

PloS one, (2015).10 9 10.1371/journal.pone.0138149.

Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial.

FIELDING, KL; Charalambous, S; Hoffmann, CJ; Johnson, S; Tlali, M; Dorman, SE; VASSALL, A; CHURCHYARD, GJ; GRANT, AD;

2015

Trials, (2015).16 1 10.1186/s13063-015-0650-0.

Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial.

Liu, X; LEWIS, JJ; Zhang, H; Lu, W; Zhang, S; Zheng, G; Bai, L; Li, J; Li, X; Chen, H; Liu, M; Chen, R; Chi, J; Lu, J; Huan, S; Cheng, S; Wang, L; Jiang, S; Chin, DP; FIELDING, KL;

2015

PLoS medicine, (2015).12 9 10.1371/journal.pmed.1001876.

Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.

VYNNYCKY, E; SUMNER, T; FIELDING, KL; LEWIS, JJ; Cox, AP; HAYES, RJ; CORBETT, EL; CHURCHYARD, GJ; GRANT, AD; WHITE, RG;

2015

American journal of epidemiology, (2015).181 8 10.1093/aje/kwu320.

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

SMITH, SG; Smits, K; Joosten, SA; Van Meijgaarden, KE; Satti, I; FLETCHER, HA; Caccamo, N; Dieli, F; Mascart, F; McShane, H; DOCKRELL, HM; Ottenhoff, TH M; TBVI TB Biomarker Working Group,;

2015

PloS one, (2015).10 9 10.1371/journal.pone.0138042.

Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future".

Requena-Méndez, A; Davies, G; MOORE, DA J;

2015

Antimicrobial agents and chemotherapy, (2015).59 4 10.1128/AAC.05182-14.

PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.

HASSAN, SS; Akram, M; KING, EC; DOCKRELL, HM; CLIFF, JM;

2015

PloS one, (2015).10 9 10.1371/journal.pone.0137646.

Effective anti-tuberculosis therapy correlates with plasma small RNA.

Honeyborne, I; Lipman, MC; ECKOLD, C; Evangelopoulos, D; Gillespie, SH; Pym, A; McHugh, TD;